NYSE:BHVN Biohaven Q2 2026 Earnings Results & Report $11.46 -0.36 (-3.01%) Closing price 03:59 PM EasternExtended Trading$11.50 +0.05 (+0.40%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Biohaven missed analyst earnings expectations in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.91 versus the -$0.7610 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Biohaven EPS ResultsActual EPS-$0.91Consensus EPS -$0.7610Beat/MissMissed by -$0.1490One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersBiohaven Revenue ResultsActual RevenueN/AExpected Revenue$0.49 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBiohaven's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Biohaven Q2 2026 Earnings FAQ Did Biohaven beat earnings estimates for Q2 2026? Biohaven (NYSE:BHVN) reported earnings of -$0.91 per share for Q2 2026, missing the consensus estimate of -$0.7610. The report was announced on Monday, August 10, 2026. When is Biohaven's next earnings date? Biohaven's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biohaven on the company's earnings history page. Biohaven Earnings HeadlinesStocktwits biotech dealmaker — Viatris and GE Healthcare buy what they can sell; Biohaven and Alector sell rightsOctober 9, 2026 | msn.comBiohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in AsiaOctober 8, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 13 at 1:00 AM | InvestorPlace (Ad)Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseOctober 8, 2026 | prnewswire.comBiohaven Ltd. (NYSE:BHVN) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsOctober 8, 2026 | americanbankingnews.comBiohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026September 28, 2026 | prnewswire.comSee More Biohaven Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email. Email Address About BiohavenBiohaven (NYSE:BHVN) (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases. Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways. Its research programs span both clinical-stage and earlier-stage candidates, although the status and indications of individual programs may change as development progresses. The company was originally known as Biohaven Pharmaceutical Holding Company and developed the migraine medicines Nurtec ODT and Zavzpret. Pfizer acquired Biohaven’s commercial CGRP migraine portfolio in 2022, while the current Biohaven Ltd. retained and continued developing a separate pipeline of investigational medicines. Biohaven is headquartered in New Haven, Connecticut, and its operations and clinical-development activities serve patients and research markets internationally. Vlad Coric has served as the company’s chief executive officer.View Biohaven ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
